In the present study, we report the use of a rapid and accurate assay as a companion diagnostic tool for the analysis of G12D and G13D mutations of the KRAS gene in CRC samples, which can provide better information for anti-EGFR drug treatment (Figure 1). This evidence concerns the gene KRAS and colorectal carcinoma.